Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00536341 · ClinicalTrials.gov registry record · Phase 1
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study of Chronic Lymphocytic Leukemia, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 6
- Study locations
NCT00536341 is a Phase 1 study of Chronic Lymphocytic Leukemia that has completed, run by SCRI Development Innovations. The registered enrollment target is 64 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (65% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00536341, a Phase 1 study of Chronic Lymphocytic Leukemia, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase I/II trial will combine fludarabine, rituximab, and lenalidomide in untreated or minimally treated (Phase I only) CLL patients, employing fixed doses of fludarabine and rituximab, using a schedule similar to that examined by investigators at MD Anderson (J Clin Oncol 23(18):4079-88, 2005). Given that the optimal dose and schedule is not currently known, this trial will perform a phase I component followed by a phase II examination to further explore this regimen's activity.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Rituximab
- DRUG lenalidomide
Study Locations (6)
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Hospital Cancer Institute - Orlando
Maryland
- Center for Cancer and Blood Disorders - Bethesda
- National Capital Clinical Research Consortium - Bethesda
South Carolina
- South Carolina Oncology Associates, PA - Columbia
Tennessee
- Tennessee Oncology, PLLC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00536341
The ClinicalTrials.gov registry entry for NCT00536341 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (65% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Fludarabine is the first listed.
NCT00536341 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, Maryland, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00536341 about?
NCT00536341 is a clinical study titled "Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)". This phase I/II trial will combine fludarabine, rituximab, and lenalidomide in untreated or minimally treated (Phase I only) CLL patients, employing fixed doses of fludarabine and rituximab, using a schedule similar to that examined by investigators at MD Anderson (J Clin Oncol 23(18):4079-88, 2005)...
What is the current status of trial NCT00536341?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2008-01. Estimated completion is 2016-11.
What conditions does trial NCT00536341 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT00536341?
The interventions under investigation include: Fludarabine (DRUG), Rituximab (DRUG), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00536341?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00536341 being conducted?
This trial has 6 study locations across Florida, Maryland, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.